Government Intervention into Drug Pricing: Part 3
Performance Metrics Point Of View
White Papers
Government Intervention into Drug Pricing: Part 2
Government Intervention into Drug Pricing: Part 1
Herspiegel Consulting Expands Market Access Support for Clients
CREATES Act Hopes to Spur Generic Competition in Pharmaceutical Market
Cigna’s Initiative to Lower the Out-Of-Pocket Cost of Insulin
The Four Key Elements of Successful New Product Planning
Commercial Launch Readiness for Pharmaceutical and Biotechnology Start-ups
DigiPharma Connect Recap – Debriefing DigiPharma Connect
Celebrating International Women’s Day
Innovative Drug Pricing via “Netflix Model”
FDA Real-World Evidence Program Framework: Implications for Pharmaceutical Companies
BMS-Celgene Merger: Worth It?
Copay Accumulators & Maximizers
Digital Health in Pharma
Planning for 505(b)2 Commercial Success
IO Landscape
Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices
FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers
The FDA approved Dupixent for moderate-to-severe atopic dermatitis
Highly Anticipated Drug Launches in 2017
Why Drug Pricing is in the News Now and What Can Be Done About It?
Getting the Most of Consulting Engagements
Innovation in Pharma
Key Challenges Facing Obamacare Repeal and Replace Plan
How Pharma Can Prepare for the Patent Cliff
Innovation in Pharma Sees Drop in 2016
3 Pillars To Support A Winning Product Launch
Vermont Drug Price Transparency Bill
Biking for a World Without Diabetes
